Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.
Absorbable Implants
/ adverse effects
Animals
Antineoplastic Agents, Phytogenic
/ administration & dosage
Drug Delivery Systems
/ adverse effects
Drug Implants
/ adverse effects
Female
Humans
Mice, Inbred C57BL
Ovarian Neoplasms
/ drug therapy
Paclitaxel
/ administration & dosage
Peritoneal Neoplasms
/ drug therapy
Textiles
Biodegradable polymeric nanotextiles
ID8-VEGF ovarian tumor model
Intraperitoneal chemotherapy
Metronomic
Paclitaxel
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 07 2019
10 07 2019
Historique:
received:
17
03
2019
revised:
03
05
2019
accepted:
13
05
2019
pubmed:
20
5
2019
medline:
12
9
2020
entrez:
20
5
2019
Statut:
ppublish
Résumé
The objective of this study was to evaluate intraperitoneal (IP) metronomic chemotherapy using sustained release paclitaxel (PTX) delivery from electrospun biodegradable polymeric yarns woven into suturable nanotextiles. Following confirmation of in vitro PTX efficacy in ID8-VEGF epithelial ovarian cancer cells, in vivo studies were performed upon surgical peritoneal implantation of nanotextile implants in orthotopic, syngeneic ID8-VEGF tumor-bearing C57BL/6 mice. In comparison to the clinical PTX-solution, there was a significant enhancement of anti-tumor efficacy and safety with PTX-nanotextiles. After 35-days, the peritoneum of tumor-bearing mice with PTX-nanotextiles was completely devoid of tumor nodules and ascitic fluid. Additionally, VEGF levels measured in peritoneal lavage fluid were 300-fold lower compared to PTX-solution and 600-fold lower as compared to untreated tumor-bearing animals. PTX-solution treated group also developed severe metastatic lesions and progressive ascitic fluid buildup. More importantly, no signs of systemic/ organ toxicity were observed in PTX-nanotextile implanted mice, unlike the systemic toxic effects induced by PTX-solution. Collectively, our results show the therapeutic and safety advantages offered by combining clinically translatable metronomic low-dose chemotherapy and IP pharmacokinetics using biodegradable nanotextile implants in addressing the challenges of late-stage ovarian cancer.
Identifiants
pubmed: 31103675
pii: S0168-3659(19)30270-6
doi: 10.1016/j.jconrel.2019.05.022
pmc: PMC6602817
mid: NIHMS1530068
pii:
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Drug Implants
0
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
29-40Subventions
Organisme : NCI NIH HHS
ID : R21 CA179652
Pays : United States
Organisme : NCI NIH HHS
ID : R56 CA198492
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
J Clin Pathol. 2002 Jan;55(1):27-31
pubmed: 11825920
Carcinogenesis. 2017 Oct 1;38(10):945-952
pubmed: 28575150
J Clin Oncol. 2006 Feb 20;24(6):988-94
pubmed: 16461779
J Control Release. 2011 Oct 30;155(2):237-47
pubmed: 21497176
Mol Aspects Med. 2014 Oct;39:110-25
pubmed: 23811037
BMC Cancer. 2007 Apr 15;7:65
pubmed: 17433113
Cancer Chemother Pharmacol. 2015 May;75(5):1075-87
pubmed: 25898813
Cancer Res. 2009 May 1;69(9):3918-26
pubmed: 19383919
Cancer Lett. 2017 Aug 1;400:243-251
pubmed: 28017892
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 May;9(3):
pubmed: 28185434
Cancer Biol Ther. 2009 Aug;8(16):1596-603
pubmed: 19738426
Mol Pharm. 2013 Sep 3;10(9):3315-22
pubmed: 23924289
J Ovarian Res. 2009 Sep 28;2(1):12
pubmed: 19781107
Int J Appl Basic Med Res. 2012 Jul;2(2):111-6
pubmed: 23776823
Int J Gynecol Cancer. 2015 Feb;25(2):214-21
pubmed: 25415075
Anticancer Res. 2006 Jul-Aug;26(4B):2785-9
pubmed: 16886597
Cancer. 1990 Feb 1;65(3):578-85
pubmed: 2297647
Ann Surg Oncol. 2013 May;20(5):1684-93
pubmed: 23128939
Carcinogenesis. 2000 Apr;21(4):585-91
pubmed: 10753190
Ann Clin Lab Sci. 2006 Autumn;36(4):475-8
pubmed: 17127738
Eur J Pharm Biopharm. 2016 Jul;104:251-9
pubmed: 27185379
Oncologist. 2004;9 Suppl 1:2-10
pubmed: 15178810
Nanomedicine (Lond). 2008 Dec;3(6):761-76
pubmed: 19025451
Anticancer Drugs. 2003 Jan;14(1):13-9
pubmed: 12544254
Cancer. 1997 Mar 15;79(6):1225-33
pubmed: 9070502
Expert Opin Drug Deliv. 2018 May;15(5):481-494
pubmed: 29488406
Cancer Lett. 2002 Feb 8;176(1):111-8
pubmed: 11790460
Br J Cancer. 2008 Dec 16;99(12):2037-43
pubmed: 19034272
Drug Metab Dispos. 1995 Jul;23(7):713-7
pubmed: 7587959
Gynecol Oncol. 2008 Feb;108(2):385-94
pubmed: 18036641
ACS Appl Mater Interfaces. 2016 Mar 23;8(11):6925-34
pubmed: 26936629
Nat Rev Cancer. 2013 Apr;13(4):273-82
pubmed: 23426401
Cancer Metastasis Rev. 2012 Jun;31(1-2):143-62
pubmed: 22101807
Lancet Oncol. 2000 Oct;1:86-93
pubmed: 11905673
Semin Cancer Biol. 2015 Apr;31:16-27
pubmed: 24956577
Anticancer Res. 2013 Apr;33(4):1317-24
pubmed: 23564768
Nat Rev Clin Oncol. 2016 Apr;13(4):255-61
pubmed: 26787282
Nano Lett. 2015 Aug 12;15(8):5420-6
pubmed: 26214718
Arch Pathol Lab Med. 2013 Feb;137(2):275-9
pubmed: 23368871
Cancer Lett. 2019 Oct 1;461:1-9
pubmed: 31288064
Pharmacology. 2008;81(4):317-24
pubmed: 18322419
Mol Cancer Ther. 2008 Mar;7(3):630-7
pubmed: 18347149
Biomacromolecules. 2014 Nov 10;15(11):4187-94
pubmed: 25251833
Cancer Res. 2002 Dec 1;62(23):6938-43
pubmed: 12460910
Hum Pathol. 2007 Jun;38(6):926-34
pubmed: 17397905
Nanomedicine. 2019 Jan;15(1):274-284
pubmed: 30343013
Eur J Cancer. 2001 Sep;37(13):1590-8
pubmed: 11527683
Toxicol Pathol. 2006;34(5):466-503
pubmed: 17067940
Reprod Sci. 2011 Aug;18(8):763-71
pubmed: 21421899
J Control Release. 2015 Dec 28;220(Pt A):358-367
pubmed: 26548976
N Engl J Med. 2004 Dec 9;351(24):2519-29
pubmed: 15590954
Adv Anat Pathol. 2009 Sep;16(5):267-82
pubmed: 19700937
J Control Release. 2012 Mar 28;158(3):386-92
pubmed: 22178261
Expert Opin Drug Saf. 2007 Sep;6(5):609-21
pubmed: 17877447
Oncol Lett. 2018 Jan;15(1):588-591
pubmed: 29285202
J Control Release. 2016 Aug 10;235:91-98
pubmed: 27238443
J Am Assoc Lab Anim Sci. 2010 Mar;49(2):202-6
pubmed: 20353696
Mol Cancer Ther. 2010 Apr;9(4):996-1006
pubmed: 20371722
Drug Deliv Transl Res. 2014 Apr 1;4(2):203-9
pubmed: 24816829
BJOG. 2012 Jan;119(2):150-9
pubmed: 22017885
Nat Rev Cancer. 2004 Jun;4(6):423-36
pubmed: 15170445
Surg Pathol Clin. 2010 Mar;3(1):83-107
pubmed: 26839028
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802
pubmed: 23880506
Cancer Res. 2000 Apr 1;60(7):1878-86
pubmed: 10766175
Tissue Eng Part C Methods. 2015 Jan;21(1):23-34
pubmed: 24745555
N Engl J Med. 2006 Jan 5;354(1):34-43
pubmed: 16394300
Chemother Res Pract. 2015;2015:197871
pubmed: 25685555